tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2015 Sep 16. pii: CVI.00288-15. [Epub ahead of print]
[h=1]Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes.[/h] Seo YB[SUP]1[/SUP], Baek JH[SUP]2[/SUP], Lee J[SUP]1[/SUP], Song JY[SUP]3[/SUP], Lee JS[SUP]2[/SUP], Cheong HJ[SUP]4[/SUP], Kim WJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects in comparison with non-diabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012/2013 influenza season. The study vaccine was a standard dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination, 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and non-diabetic groups satisfied all of the criteria of the CHMP and immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well-tolerated and all reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups except for the seroprotection rate for the A/H1N1 strain, which was significantly lower in the elderly diabetic group than in the elderly non-diabetic group. However, long-term immunogenicity was associated with age and pre-vaccination titer regardless of diabetes in multivariate analysis.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26376926 [PubMed - as supplied by publisher]
[h=1]Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes.[/h] Seo YB[SUP]1[/SUP], Baek JH[SUP]2[/SUP], Lee J[SUP]1[/SUP], Song JY[SUP]3[/SUP], Lee JS[SUP]2[/SUP], Cheong HJ[SUP]4[/SUP], Kim WJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects in comparison with non-diabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012/2013 influenza season. The study vaccine was a standard dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination, 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and non-diabetic groups satisfied all of the criteria of the CHMP and immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well-tolerated and all reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups except for the seroprotection rate for the A/H1N1 strain, which was significantly lower in the elderly diabetic group than in the elderly non-diabetic group. However, long-term immunogenicity was associated with age and pre-vaccination titer regardless of diabetes in multivariate analysis.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26376926 [PubMed - as supplied by publisher]